A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs ABBV 075 (Primary)
- Indications Acute myeloid leukaemia; Breast cancer; Cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 24 Aug 2017 Planned End Date changed from 8 May 2018 to 21 Aug 2018.
- 15 Dec 2016 Planned number of patients changed from 100 to 150.
- 08 Aug 2016 Planned number of patients changed from 78 to 100.